Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

For the first time ever, researchers from the Norwegian University of Science and Technology (NTNU) have identified new ...

There may be a "promising new strategy" in combating aggressive forms of prostate cancer, according to a new study. Researchers at Flinders University and the University of South Australia ...

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by ...

A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer cell models in the ...

Researchers have detected microplastics in nearly all prostate cancer tumors examined in a new study. Tumor tissue contained about 2.5 times more plastic than nearby healthy prostate tissue.

Former U.S. President Joe Biden speaks at a conference hosted by the Advocates, Counselors, and Representatives for the Disabled on April 15, 2025 in Chicago. Former U.S. President Joe Biden speaks at ...